DISRUPT PAD III Randomized Clinical Trial

Shockwave Intravascular Lithotripsy (IVL) provides superior vessel prep and excellent long-term results in calcified vessels while preserving future treatment options.

DISRUPT PAD III RCT logo
DISRUPT PAD III Randomized Clinical Trial logo

DISRUPT PAD III: The Largest-ever Randomized Study of Severely Calcified Peripheral Lesions 

Statistics Callout

This section presents key statistical information with numbers and descriptions.

  • 45
    Global sites
  • 306
    Superficial femoral artery (SFA)/popliteal lesions randomized to Shockwave IVL or percutaneous transluminal angioplasty (PTA)
  • 83
    %
    Severe calcification by Peripheral Academic Research Consortium (PARC), an independent core lab*
  • 129 mm
    Average calcified length by an independent core lab*

*Data refers to Shockwave IVL arm of randomized study 

Accordion Section

Intravascular Lithotripsy for Peripheral Artery Calcification: Disrupt PAD III RCT Mid-Term Outcomes

DISRUPT PAD III RCT Mid-Term Outcomes

Watch Dr. Bill Gray and Dr. Sahil Parikh discuss the significance of the PAD III RCT one- and two-year results.

Check out JSCAI’s “Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized DISRUPT PAD III Trial.”

See All Clinical Evidence
See All Clinical Evidence
  • DISRUPT BTK II
    Global prospective, multi-center, single-arm study assessing the safety and effectiveness of Shockwave peripheral IVL in treating long, calcified BTK lesions.
    Peripheral IVL
  • DISRUPT PAD II
    Core lab adjudicated, long-term, multi-center study exclusively enrolling heavily calcified lesions building upon DISRUPT PAD I.
    Peripheral IVL
  • DISRUPT PAD III Observational Study
    The largest prospective real-world evidence for the treatment of complex, heavily calcified peripheral arterial disease (PAD).
    Peripheral IVL